Shares of Biogen Inc closed the previous trading session at 271.34 up +0.31 0.11% with 1,376,563 shares trading hands. The post Insider Trading Activity Biogen Inc (NASDAQ:BIIB) – CEO Bought 1,402 shares of Stock appeared first on …
Biogen Idec Inc. (BIIB) was a big mover last session with shares rising over 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the uptrend for the company …
Based on fundamentals, market trends, company events and news, and other factors, equity analysts assign price targets and recommendations to buy or sell a stock. The following graph shows how a survey of multiple analysts recommend …
Mr. Robert W. Pangia is an Independent Director of the Company. Mr. Pangia served as a director of the Company from 1997 to 2003 during the period the Company was operated as IDEC Pharmaceuticals, and has served as a director …
Currently, the Vetr crowd's average target price for the stock is up at $295.39, which is still below the average analyst target price of $332.00. Less than 2 percent of Vetr users are holding BIIB in their watch lists. Latest Ratings for BIIB
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets …
(Reuters) - Biogen Inc's second-quarter profit smashed estimates on Tuesday, boosted by strong sales of its spinal muscular atrophy (SMA) drug, Spinraza, which is priced at $750,000 for the first year of therapy. Buoyed by the …